BioCentury
ARTICLE | Financial News

Urogen rises in first trading day

May 4, 2017 10:24 PM UTC

Urogen Pharma Ltd. (NASDAQ:URGN) gained $0.98 to $13.98 in its first day of trading Thursday after raising $58.2 million in an upsized IPO. The oncology company priced the offering after market hours Wednesday (see BioCentury Extra, May 3).

UroGen's lead candidate MitoGel is in Phase III testing to treat upper tract urothelial carcinoma (UTUC). MitoGel has Orphan Drug designation for the indication...

BCIQ Company Profiles

UroGen Pharma Ltd.